Biotech Values

[DewDiligence]

ABBV will report phase-3 top-line HCV data from some of the trials listed in #msg-92959364 this year data via press release(s); no further details available, but the first PR will presumably include SAPHIRE-1 and SAPHIRE-2.

ABBV’s 3Q13-results PR this morning said the HCV-data PR(s) would begin in 4Q13 (i.e. the current quarter); however, on today’s CC, ABBV’s CEO said the PR(s) would come in “late 2013,” which I interpret to mean after AASLD.